文章摘要
Ibalizumab治疗耐多药HIV-1感染的研究进展
Research advances of ibalizumab in the treatment of multidrug-resistant HIV-1 infection
  
DOI:10.3969/j.issn.1007-8134.2022.02.016
中文关键词: ibalizumab  耐多药  抗病毒活性  单克隆抗体  交叉耐药  药代动力学特性  临床研究
英文关键词: ibalizumab  multidrug-resistance  antiviral activity  monoclonal antibody  cross-resistance  pharmacokinetic property  clinical trial
基金项目:贵州省卫生健康委科学技术基金(2019-1-082);贵州省科技计划项目([2020]1Y299);国家自然科学基金(82060123) [作者单位] 550004?贵阳,贵州医科大学附属医院感染科(李宏、万艳)
作者单位
万 艳 贵阳贵州医科大学附属医院感染科 
李 宏 贵阳贵州医科大学附属医院感染科 
摘要点击次数: 519
全文下载次数: 0
中文摘要:
      [摘要] Ibalizumab是一种人源化免疫球蛋白G4单克隆抗体,其在阻断HIV-1进入CD4+ T淋巴细胞的同时,可保持人体正常免疫功能。鉴于此,临床逐步将ibalizumab与其他抗反转录病毒药物联合应用于治疗耐多药HIV-1感染,相关研究已经取得了较大进展。目前,ibalizumab是第一个被美国FDA批准用于治疗HIV-1感染的单克隆抗体,有望成为治疗耐多药HIV-1感染的新选择。本文综述了ibalizumab治疗成人耐多药HIV-1感染的药理学特性及临床疗效,为耐多药HIV-1感染的治疗提供参考。
英文摘要:
      [Abstract] Ibalizumab, a humanized immunoglobulin G4 monoclonal antibody, blocks HIV-1 entry into CD4+ T lymphocytes while preserving normal immune function of human body. Thereforem ibalizumab in combination with other antiretroviral(s) is indicated in clinical treatment of multidrug-resistant HIV-1 infection, and has achieved great progress in related research. Ibalizumab is the first monoclonal antibody approved by the U.S. FDA for the treatment of HIV-1 infection and provided a new choice for the treatment of multi drug-resistant HIV-1 infection. This article reviews the pharmacological properties and clinical efficacy of ibalizumab in the treatment of adult multidrug-resistant HIV-1 infection, and provides references for the treatment of multidrug-resistant HIV-1 infection.
HTML   查看全文   下载PDF阅读器
关闭